Efficacy and Safety of Octanorm (Cutaquig®) in Adults With Primary Immunodeficiencies With Predominant Antibody Deficiency: A Prospective, Open-Label Study
Immunotherapy - United Kingdom
doi 10.2217/imt-2020-0012
Full Text
Open PDFAbstract
Available in full text
Date
March 26, 2020
Authors
Publisher
Future Medicine Ltd